Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by periods of clinical instability called 'acute exacerbations' (AECOPD). 1 Although no consensus has been reached on a clear definition of 'exacerbation', 2 the Canadian Thoracic Society refers to such episodes as 'a sustained worsening dyspnea, cough or sputum production leading to an increase in the use of maintenance medications and/or supplementation with additional medications'. 3 AECOPD represent important events in the course of the disease. They are associated with deterioration of quality of life. 4 Repeated AECOPD result in further decline in lung function and contribute to disease progression. 5 Mortality is also related to the frequency of severe exacerbations requiring hospitalization. 6 AECOPD are usually treated empirically with short courses of oral steroids (Prednisone) and broad spectrum antibiotics. The rationale is that airways inflammation found in stable COPD is amplified during acute exacerbations. 7 Also, more than half of the exacerbations are caused by bacterial bronchial infections. 8 Prompt initiation of treatment resulting in improvement of exacerbation recovery and reduced risk of hospitalization, 9 patients are often taught to recognize the early manifestations of AECOPD. 10 In addition, patients are often given a prescription for a short course of oral steroids and antibiotics for selfadministration during an acute exacerbation. However, the real effect of such prescriptions on heath care and drug utilization is still unknown. It is of concern that these self-administered prescriptions could lead to an increased and inappropriate utilization of systemic steroids and antibiotics. The objective of this study was to ORIGINAL PAPER Self-administered prescriptions of oral steroids and antibiotics in chronic obstructive pulmonary disease: are we doing more harm than good?
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Methods

Patients
This study took place in the self-management programme of two hospitals affiliated to Laval University, Quebec City, Canada. This programme offers integrated care, especially education, to patients with moderate and severe COPD at high risk of exacerbations.
Patients are included in the program if they meet the following criteria: 1) diagnosis of COPD supported by a history of past or active smoking, 2) a forced expiratory volume in one second (FEV 1 ) Ͻ50% of the predicted value, and a FEV 1 /FEVC ratio Ͻ60%; 3) at least one hospitalization or two unplanned medical visits within the year that preceded their registration to the programme. Patients with bronchiectasis as the main cause of airways obstruction were excluded. All the patients were at their first registration in a selfmanagement programme.
Self-management programme and self-administered prescriptions
The self-management programme, which is proven to improve health status and reduce utilization of health care services, 10 includes patient education, close follow-up by nurses and/or respiratory therapists (called 'case managers') and an action plan for AECOPD. The action plan is customized for each patient and includes a contact list and a symptommonitoring list linked to appropriate therapeutic actions. For some patients, the action plan also includes a prescription for a short course of Prednisone and/or antibiotics for self-administration. The decision to provide patients with a self-administered prescription is left to the treating physician. The purpose of our study was to compare the medical care and medication utilization in those who received a self-administered prescription of Prednisone and/or antibiotics with those who did not. Patients allocation in the 'prescription' or the 'control' groups was therefore non-randomized.
Study period
Patients registered in the programme between March 2000 and June 2005 were included. We computed the number of unplanned medical visits (including hospitalizations) and the utilization of systemic steroids (number of short courses and number of days on Prednisone) and antibiotics (number of short courses) over a period of six months before and after the day they received their self-administered prescription (the 'index date'). The date of registration and the 'index date' did not necessarily coincide since patients in the 'prescription' group may have received their selfadministered prescription days or weeks after their registration to the programme. For each patient, the number of days between the date of registration and the index date was calculated. We called this interval of time the 'latency'. In order to study similar periods in the control group, the mean latency in the 'prescription' group was used to determine the index date in the control group. For each patient in the control group, we determined the index date by adding the mean latency to the registration date ( Figure 1 ).
Data collection
After receiving written consent from the patients, we extracted data from their hospital and community pharmacy files. Gender, age, FEV 1 , smoking status, diagnosis of diabetes and the intervention received in the self-management programme were recorded. For those in the 'prescription' group, the details of the selfadministered prescription (dose of Prednisone, type of antibiotics) were also noted. Health care utilization was recorded from the number of unplanned medical visits and hospitalizations for respiratory diagnoses.
Length of stay was also noted. Drug utilization over a period of six months before and after the index date was determined from 1) the number of short courses of Prednisone, 2) the number of days on Prednisone, 3) the number of short courses of antibiotics, and 4) the number of days on antibiotics. Steroid-dependant patients were excluded from the analysis of corticosteroids use. Similarly, patients receiving antibiotics on a prophylactic basis were excluded from the analysis of antibiotics use.
Statistics
Baseline clinical characteristics were compared between groups using unpaired t-tests for the continuous variables and chi-square tests for the categorical variables. A generalized mixed model was used to analyse data before and after the 'index date'. According to the distribution of the variables, the Poisson or the normal distributions were used. The comparisons of outcomes after the 'index date' were all adjusted for the results obtained before the 'index date'. For all variables, the log transformation was used as a link function into the statistical models. The level of statistical significance was set at the 0.05 level.
Results
Population
Eighty-nine patients were included. Forty-six received a self-administered prescription. Patients' baseline characteristics are summarized in Table 1 . We found no significant difference between the two groups in terms of gender, severity of disease, smoking history and intervention received within the self-management programme. Most self-administered prescriptions consisted in Prednisone and a fluoriquinolone, which is consistent with current guidelines. 11 On average, the 'latency' (ie, the number of days between the date of registration and the index date) was 26 days.
Health care and medication utilization
In the period of six months that preceded the index date, there was no significant difference between the two groups regarding the number of unplanned medical visits for respiratory diagnoses, the number of hospitalizations and the total number of days in hospital.
In addition, in the same period, we found no significant difference in steroids and antibiotics utilization between the two groups ( Table 2) .
However, following the 'index date', we found significant differences in the number of short courses of steroids and antibiotics. The changes in health care and medication utilization are presented in Table 3 . The difference between the 'prescription' and the control groups was more obvious in the number of days on steroids. The patients who received a self-administered prescription spent on average 26 days on Prednisone during the six months that followed the 'index date', whereas those who did not received a prescription spent on average eight days on Prednisone. *The difference between the number of patients who received a selfadministered prescription of antibiotics (n ϭ38) and the total number of prescriptions (29 ϩ10 ϩ7) is because patients may have received more than one self-administered prescription over the study period.
Discussion
The results of this study indicated that self-administered prescriptions may increase steroids and antibiotics utilization in patients with moderate to severe COPD, without reducing the number of unplanned medical visits. Although oral steroids and antibiotics represent standard therapy in acute exacerbations of COPD, 12 our findings are of concern for clinicians involved in selfmanagement programmes and call for a reappraisal of the benefits and risks of systemic steroids and antibiotics in such circumstances. Taken together, the evidence that systemic steroids significantly improves clinical outcome is not that impressive. A recent Cochrane review of systemic corticosteroids for acute exacerbations in COPD concluded that systemic steroids reduce treatment failure and the need for additional medical treatment, at the expense of significant risk of adverse drug reactions however. 13 Of note, this meta-analysis included inpatients treated with either oral or intravenous steroids as well as outpatients treated with Prednisone only. Treatment failure (defined as hospital readmission or return to emergency department) within 30 days of therapy was reduced by half in treated patients. In the seven trials that contributed to the meta-analysis, 72% of those allocated to placebo experienced a good outcome anyway. The authors of the meta-analysis found no effect of systemic steroids on mortality. The latest trial that was limited to outpatients treated with Prednisone yielded results that are consistent with those of the meta-analysis (relapse rate at 30 days: Prednisone: 27%; placebo: 43%; P ϭ0.05). 14 Finally, in the trial with the longest follow-up period, significant treatment benefits were no longer evident at six months. 15 The same observations apply to oral antibiotics in the course of an acute exacerbation. In the randomized trial by Anthonisen et al., 16 the success rate with antibiotics was 68%, whereas it was 55% with placebo. Differences in success rates between antibiotics and placebo increased as the likelihood of bacterial infection increased, emphasizing the need of a proper assessment of symptoms before the initiation of therapy.
The results of these trials must be balanced against the potential short and long-term side effects of systemic steroids (that include, among others, hyperglycemia, secondary infections, mood changes, osteoporosis, myopathy and cataracts) and those of oral antibiotics (that include, among others, post-antibiotic diarrhea and development of bacterial resistance). In this regard, the appropriateness of the utilization of both drugs must be questioned each time a prescription is written.
We acknowledge several limitations to our retrospective study. First, the comparison between the patients who received a self-administered prescription and those who did not was not randomized. One could argue that the patients who received a prescription were probably sicker than those who did not, which could explain the differences we observed. However, this hypothesis is not supported by the baseline comparison of the two study groups (Tables 1 and 2) . Second, we did not collect any information on the symptoms of exacerbation and the indications of steroids and antibiotics. Although all patients had equal access to a case manager, it is probable that many exacerbations remained unreported, as reported by others in observational studies. 17, 18 Whether the utilization of Prednisone and antibiotics was appropriate is therefore unknown. Nevertheless, there is indirect evidence that many treatments were indeed inappropriate. We anticipated that patients who were given a self-administered prescription would have less unplanned medical visits and hospitalizations that those who did not benefit from such a prescription. We did not observe such difference however ( Table 3) .
Patient education in self-management programmes likely represents an important strategy to improve patients' skills to recognize exacerbations requiring Prednisone and antibiotics. Although a recent metaanalysis by Taylor et al. concluded that there is little evidence to date to support the widespread implementation of nurse-led management interventions for COPD, 19 our experience with such a programme is very positive. We designed our programme after the intervention described by Bourbeau et al. 10 whose trial was included in Taylor's meta-analysis. 19 In this trial, compared with usual care, self-management for COPD patients provided by a trained health professional significantly reduced the utilization of health care services and improved health status. Hospital admissions for exacerbation of COPD were reduced by 40% in the intervention group compared with the usual care group (P ϭ0.01), and admissions for other health problems were reduced by 57% (P ϭ0.01). Emergency department visits were reduced by 41% (P ϭ0.02) and unscheduled physician visits by 59% (P ϭ0.003). Of note, the effect of self-administered prescriptions of Prednisone and antibiotics was not tested in this trial since all patients registered in the self-management programme received such a prescription.
The results of our study questioned the current practice to often provide our patients with a prescription of systemic steroids and antibiotics for self-administration when symptoms of acute exacerbation are recognized. It also emphasized the need of a randomized trial of self-administered prescription to determine its real impact in COPD. The clinical outcomes of such a trial would be the number of unplanned medical visits (including hospitalizations), the utilization of antibiotics and corticosteroids, the changes in lung function, and COPD-specific quality of life. From Bourbeau et al's data, 10 we determined that a sample size of 150 patients (75 patients in each group) would be needed in order to demonstrate that self-administered prescriptions are associated with a 33% reduction in the number of unplanned medical visits over a one-year period.
